Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$59.44
▼ $1.18 (-1.9%)
Market data updated: 09/28 10:58 AM
Fundamentals updated: 09/28/2026
News analyzed: 09/28/2026
Market Cap
$5.60B
Day Range
$59.05 - $60.89
52-Week Range
$22.06 - $68.73
Beta
—
Next Earnings
22.10.2026
Support
$53.00
Resistance
$68.73
TVTX is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+141.6% (1Y)
Strengths: 8/26 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 110.5%
Growth
Biggest negative driver
Operating margin
Operating margin: -12.8% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 3 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 3
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
47
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
74
Quality
58
Value
50
Momentum
19
Risk
48
Sentiment
80
Fundamental
35
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Travere Therapeutics has primarily centered on its stock performance and market momentum, with analysts highlighting its strong valuation and potential upside. The company’s launch of FILSPARI FSGS and expansion of its renal pipeline have drawn attention, alongside discussions about its financial health and stock trends, including a "Buy" rating with projected 27% upside. Additionally, there was a brief mention of Nasdaq compliance regarding inducement grants, though broader industry shifts—like potential regulatory curbs on drug pricing—were noted in broader biotech discussions rather than directly tied to Travere.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Travere Therapeutics, Inc.. News trend score: 80. Reason: 8 of the last 20 articles are positive, versus 3 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
38
🎯 Conviction (vs. Emotion)
48
Psychology
50
Fundamentals
35
Technical
19
Valuation
50
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+1%
Market Narrative
45
Fundamental Reality
48
Narrative Gap
-3
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market’s dominant herding behavior reflects a lack of divergence between TVTX and its peers, despite its overvalued state (+31.3% above 200-day average) and muted momentum. Euphoria lingers due to extreme positive sentiment (98/100) and anchoring near resistance, while FOMO remains latent—evidenced by neutral volume and mid-range RSI (56). The key question is whether traders will break from the herd if sentiment shifts or resistance holds, given the narrative-reality gap (14 points).
Updated: 09/08/2026, 05:01 PM
What could change this?
👥 What the crowd believes
"Evercore ISI Group analyst raises Travere Therapeutics price target from $68 to $78"
"Travere Therapeutics sees FILSPARI FSGS launch top expectations, expands renal pipeline"
"Travere Therapeutics rated Buy with 27% upside via DCF-based fair value of ~$81"
"Travere Therapeutics stock outperforms 95% of stocks"
📈 4D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 95/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
This stock sparks a sharp divide between methodologies, with Peter Lynch and Walter Bagehot both assigning it near-perfect scores (93) for its growth potential and financial resilience, respectively. Lynch’s high score reflects his focus on underappreciated growth stocks where the market hasn’t yet recognized the company’s trajectory, while Bagehot’s endorsement highlights its strong liquidity and ability to weather financial stress. In contrast, Fisher and Smith—both quality-focused—rate it modestly (65 and 63), suggesting it lacks the exceptional durability or long-term fundamentals they prioritize. Meanwhile, the more risk-averse frameworks, like Graham’s defensive criteria (43) and Marks’ valuation/risk warnings (31), flag it as overvalued or speculative, while efficient-market theorists (36) dismiss it as unworthy of active picking. The extreme contrast between Lynch’s enthusiasm and Marks’ caution underscores whether the stock’s growth is justified or merely a speculative bubble.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 95
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 93
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 93
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 65
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 63
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 55
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 52
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 46
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 44
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 43
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 32
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 32
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 30
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 21
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 286 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 10 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
97.9%
Operating Margin
-12.8%
Net Margin
-5.2%
EBITDA Margin
-0.4%
ROE
-22.2%
ROA
-4.2%
ROIC
—
EPS
-$0.29
Cash
$93.03M
Total Debt
—
Current Ratio
2.74
Debt/Equity
—
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$1.29
Tangible Book Value per Share (Tangible NAV)
$0.01
Sentiment based on basic keywords (not AI) — 8 positive, 9 neutral, 3 negative out of the last 20 articles.
Benzinga · 24.9.2026
Yahoo · 23.9.2026
Yahoo · 23.9.2026
SeekingAlpha · 22.9.2026
Yahoo · 22.9.2026
Benzinga · 22.9.2026
Benzinga · 22.9.2026
Yahoo · 21.9.2026
Benzinga · 21.9.2026
ChartMill · 21.9.2026
Yahoo · 17.9.2026
Business Wire · 11.9.2026
Yahoo · 11.9.2026
Investor's Business Daily · 8.9.2026
Yahoo · 8.9.2026
Insider Monkey · 4.9.2026
SeekingAlpha · 31.8.2026
Yahoo · 24.8.2026
Investor's Business Daily · 24.8.2026
Investor's Business Daily · 21.8.2026
Travere Therapeutics, Inc. (TVTX) currently has a StockIQ AI score of 47/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
TVTX currently scores 47/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
TVTX's technical score is 19/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 110.5%; Earnings per share (EPS) growth: 92.9%; Net income growth: 92.1%.
Based on the real signals StockIQ computed: Operating margin: -12.8% (negative); Net margin: -5.2% (negative); ATR: 4.1% of price.
StockIQ has no recorded dividend payment history for TVTX.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 10 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Dube Eric M | Open Market Sale | 17.9.2026 | 439,688 | -101,691 | $64.59 |
| Dube Eric M | Open Market Sale | 17.9.2026 | 432,886 | -6,802 | $64.95 |
| Dube Eric M | Exercise of Derivative Securities | 17.9.2026 | 0 | -108,493 | — |
| Heerma Peter | Open Market Sale | 17.9.2026 | 117,066 | -8,282 | $65.07 |
| Dube Eric M | Exercise of Derivative Securities | 17.9.2026 | 541,379 | +108,493 | $23.34 |
| Heerma Peter | Exercise of Derivative Securities | 17.9.2026 | 125,348 | +8,282 | $22.40 |
| Heerma Peter | Exercise of Derivative Securities | 17.9.2026 | 44,837 | -8,282 | — |
| Heerma Peter | Exercise of Derivative Securities | 16.9.2026 | 289,783 | +17,717 | $26.88 |
| Heerma Peter | Open Market Sale | 16.9.2026 | 117,066 | -79,113 | $63.65 |
| Heerma Peter | Open Market Sale | 16.9.2026 | 196,179 | -93,604 | $63.25 |
| Heerma Peter | Exercise of Derivative Securities | 16.9.2026 | 272,066 | +55,000 | $15.46 |
| Dube Eric M | Open Market Sale | 16.9.2026 | 529,011 | -99,716 | $63.26 |
| Heerma Peter | Exercise of Derivative Securities | 16.9.2026 | 217,066 | +100,000 | $11.25 |
| Heerma Peter | Exercise of Derivative Securities | 16.9.2026 | 0 | -100,000 | — |
| Heerma Peter | Exercise of Derivative Securities | 16.9.2026 | 500 | -17,717 | — |
| ROTE WILLIAM E. | Exercise of Derivative Securities | 16.9.2026 | 98,547 | +350 | $17.96 |
| ROTE WILLIAM E. | Exercise of Derivative Securities | 16.9.2026 | 153,547 | +55,000 | $15.46 |
| ROTE WILLIAM E. | Exercise of Derivative Securities | 16.9.2026 | 211,047 | +57,500 | $26.88 |
| ROTE WILLIAM E. | Exercise of Derivative Securities | 16.9.2026 | 0 | -350 | — |
| ROTE WILLIAM E. | Open Market Sale | 16.9.2026 | 98,197 | -47,746 | $63.61 |
| ROTE WILLIAM E. | Open Market Sale | 16.9.2026 | 145,943 | -65,104 | $63.12 |
| Dube Eric M | Exercise of Derivative Securities | 16.9.2026 | 628,727 | +195,841 | $23.34 |
| Dube Eric M | Open Market Sale | 16.9.2026 | 432,886 | -96,125 | $63.64 |
| Dube Eric M | Exercise of Derivative Securities | 16.9.2026 | 108,493 | -195,841 | — |
| ROTE WILLIAM E. | Open Market Sale | 15.9.2026 | 130,488 | -63,907 | $61.99 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
12,955,933 shares short as of 2026-09-15 · vs. 12,004,820 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
50.8% of trading volume this week was short selling, vs. 61.8% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology